We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option.
- Authors
Yao, Tian‐Tian; Qian, Jian‐Dan; Zhu, Wen‐Yan; Wang, Yan; Wang, Gui‐Qiang
- Abstract
In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease‐19 (COVID‐19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID‐19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID‐19. Highlights: LPV is an effective agent inhibiting coronavirus in vitro and animal studies.The treatment of LPV improved outcomes of SARS and MERS patients.LPV may be a potential treatment option for COVID‐19.
- Subjects
WUHAN (China); MIDDLE East; SARS virus; MERS coronavirus; SARS disease; MIDDLE East respiratory syndrome; COVID-19; META-analysis
- Publication
Journal of Medical Virology, 2020, Vol 92, Issue 6, p556
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.25729